168 related articles for article (PubMed ID: 14559888)
1. Why do we need another antiemetic? Just ask.
Kris MG
J Clin Oncol; 2003 Nov; 21(22):4077-80. PubMed ID: 14559888
[No Abstract] [Full Text] [Related]
2. Chemotherapy-induced nausea and vomiting.
Hesketh PJ
N Engl J Med; 2008 Jun; 358(23):2482-94. PubMed ID: 18525044
[No Abstract] [Full Text] [Related]
3. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
Navari RM; Aapro M
N Engl J Med; 2016 Apr; 374(14):1356-67. PubMed ID: 27050207
[No Abstract] [Full Text] [Related]
4. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
[TBL] [Abstract][Full Text] [Related]
5. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
6. [ESMO 2004. Nausea and vomiting caused by chemotherapy: improving the treatment].
Longo F; Mansueto G
Tumori; 2005; 91(1):suppl 36-48. PubMed ID: 15850022
[No Abstract] [Full Text] [Related]
7. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
[TBL] [Abstract][Full Text] [Related]
8. Best practice management of CINV in oncology patients: I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches.
Frame DG
J Support Oncol; 2010; 8(2 Suppl 1):5-9. PubMed ID: 20629452
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
10. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
11. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
[TBL] [Abstract][Full Text] [Related]
12. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
[TBL] [Abstract][Full Text] [Related]
13. Antiemesis.
Ettinger DS; Bierman PJ; Bradbury B; Comish CC; Ellis G; Ignoffo RJ; Kirkegaard S; Kloth DD; Kris MG; Lim D; Markiewicz MA; McNulty R; Nabati L; Todaro B; Urba S; Yowell S;
J Natl Compr Canc Netw; 2007 Jan; 5(1):12-33. PubMed ID: 17239323
[No Abstract] [Full Text] [Related]
14. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
15. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin antagonism and chemotherapy-induced emesis.
Shanahan F; O'Sullivan GC
Am J Gastroenterol; 1999 Nov; 94(11):3368-9. PubMed ID: 10566748
[No Abstract] [Full Text] [Related]
17. [Prevention of nausea and vomiting. Aprepitant, the first therapeutic acting NK-1 receptor antagonist].
Nieber K; Schoppmeyer K
Pharm Unserer Zeit; 2007; 36(5):373-80. PubMed ID: 17722144
[No Abstract] [Full Text] [Related]
18. CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
Wilbur MB; Birrer MJ; Spriggs DR
N Engl J Med; 2016 Jul; 375(2):177-9. PubMed ID: 27410928
[No Abstract] [Full Text] [Related]
19. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
20. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
Tsukahara K; Nakamura K; Motohashi R; Sato H; Endo M; Katsube Y; Ueda Y; Suzuki M
Acta Otolaryngol; 2014 Nov; 134(11):1198-204. PubMed ID: 25315920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
